TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
55.78
-0.41 (-0.73%)
Sep 30, 2026, 4:00 PM EDT - Market closed
TG Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 799.54 | 616.29 | 329 | 233.66 | 2.79 | 6.69 | |
Revenue Growth | 76.08% | 87.32% | 40.80% | 8290.02% | -58.36% | 4300.66% |
Cost of Revenue | 140.94 | 100.71 | 38.49 | 14.13 | 0.27 | 0.79 |
Gross Profit | 658.6 | 515.57 | 290.52 | 219.53 | 2.52 | 5.9 |
Selling, General & Admin | 296.47 | 232.03 | 154.3 | 122.71 | 95.48 | 128.09 |
Research & Development | 225.8 | 160.22 | 94.29 | 76.19 | 125.35 | 222.58 |
Operating Expenses | 522.27 | 392.25 | 248.59 | 198.9 | 220.84 | 350.67 |
Operating Income | 136.33 | 123.32 | 41.93 | 20.63 | -218.32 | -344.77 |
Interest Expense | -37.49 | -26.73 | -24.03 | -12.62 | -10.19 | -5.64 |
Other Non Operating Income (Expenses) | 11.92 | 10.79 | 7.69 | 5.04 | 4.7 | 2.31 |
Pretax Income | 101.6 | 107.39 | 25.59 | 13.06 | -223.81 | -348.1 |
Income Tax Expense | -339.89 | -339.79 | 2.21 | 0.39 | - | - |
Net Income | 441.49 | 447.18 | 23.38 | 12.67 | -223.81 | -348.1 |
Net Income to Common | 441.49 | 447.18 | 23.38 | 12.67 | -223.81 | -348.1 |
Net Income Growth | 630.24% | 1812.41% | 84.52% | - | - | - |
Shares Outstanding (Basic) | 143 | 144 | 145 | 142 | 135 | 132 |
Shares Outstanding (Diluted) | 159 | 161 | 160 | 149 | 135 | 132 |
Shares Change | -5.56% | 0.67% | 7.96% | 9.67% | 2.41% | 14.64% |
EPS (Basic) | 3.10 | 3.10 | 0.16 | 0.09 | -1.65 | -2.63 |
EPS (Diluted) | 2.77 | 2.77 | 0.15 | 0.09 | -1.65 | -2.63 |
EPS Growth | 667.52% | 1746.67% | 68.03% | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 17.39 | -24.99 | -40.56 | -31.41 | -176.18 | -296.04 |
Free Cash Flow Per Share | 0.11 | -0.15 | -0.25 | -0.21 | -1.30 | -2.24 |
Gross Margin | 82.37% | 83.66% | 88.30% | 93.95% | 90.48% | 88.19% |
Operating Margin | 17.05% | 20.01% | 12.74% | 8.83% | -7838.99% | -5154.28% |
Profit Margin | 55.22% | 72.56% | 7.11% | 5.42% | -8036.34% | -5204.08% |
Free Cash Flow Margin | 2.17% | -4.05% | -12.33% | -13.44% | -6326.18% | -4425.70% |
EBITDA | 136.45 | 123.38 | 42 | 20.84 | -218.01 | -344.49 |
EBITDA Margin | 17.07% | 20.02% | 12.77% | 8.92% | - | - |
D&A For EBITDA | 0.12 | 0.06 | 0.07 | 0.21 | 0.3 | 0.28 |
EBIT | 136.33 | 123.32 | 41.93 | 20.63 | -218.32 | -344.77 |
EBIT Margin | 17.05% | 20.01% | 12.74% | 8.83% | - | - |
Effective Tax Rate | - | - | 8.64% | 2.99% | - | - |
Revenue as Reported | 799.54 | 616.29 | 329 | 233.66 | 2.79 | 6.69 |